{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:36:56Z","timestamp":1786412216260,"version":"build-2736575974"},"reference-count":200,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1124\/pharmrev.123.000938","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T22:55:13Z","timestamp":1702508113000},"page":"228-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes"],"prefix":"10.1016","volume":"76","author":[{"given":"K.T.","family":"Babalola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3809-3153","authenticated-orcid":false,"given":"M.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0262-5170","authenticated-orcid":false,"given":"R.","family":"Ganugula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5606-401X","authenticated-orcid":false,"given":"M.N.V. Ravi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.123.000938_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/IJNRD.S335371","article-title":"Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis","volume":"14","author":"Alamilla-Sanchez","year":"2021","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1124\/pharmrev.123.000938_bib3","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.3390\/polym13162815","article-title":"A Comprehensive Review of Microneedles: Types, Materials, Processes, Characterizations and Applications","volume":"13","author":"Aldawood","year":"2021","journal-title":"Polymers (Basel)"},{"key":"10.1124\/pharmrev.123.000938_bib4","first-page":"2733","article-title":"Advanced drug delivery to the lymphatic system: lipid-based nanoformulations","volume":"8","author":"Ali Khan","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"10.1124\/pharmrev.123.000938_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1208\/s12248-014-9708-2","article-title":"Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance","volume":"17","author":"Andorko","year":"2015","journal-title":"AAPS J"},{"key":"10.1124\/pharmrev.123.000938_bib6","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1002\/art.30424","article-title":"Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-\/- IL-2R\u03b3-\/- mice: a promising model for studying human disease","volume":"63","author":"Andrade","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.123.000938_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0000000000000773","article-title":"The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy","volume":"33","author":"Appleton","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102374","article-title":"Inflammatory markers in systemic lupus erythematosus","volume":"110","author":"Aringer","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1124\/pharmrev.123.000938_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.autrev.2011.05.001","article-title":"Therapeutic blockade of TNF in patients with SLE-promising or crazy?","volume":"11","author":"Aringer","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1124\/pharmrev.123.000938_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jso.21535","article-title":"Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection","volume":"102","author":"Ashikaga","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1124\/pharmrev.123.000938_bib11","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.celrep.2016.04.007","article-title":"Targeted Delivery of Immunomodulators to Lymph Nodes","volume":"15","author":"Azzi","year":"2016","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.123.000938_bib12","first-page":"2954","article-title":"TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice","volume":"119","author":"Baluk","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.123.000938_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40744-020-00212-9","article-title":"Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New","volume":"7","author":"Basta","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1124\/pharmrev.123.000938_bib14","doi-asserted-by":"crossref","first-page":"365ra157","DOI":"10.1126\/scitranslmed.aag2374","article-title":"Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals","volume":"8","author":"Bellinger","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.123.000938_bib15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"118","author":"Bhatt","year":"2008","journal-title":"Circulation"},{"key":"10.1124\/pharmrev.123.000938_bib16","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00198-003-1553-6","article-title":"The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Bhattoa","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1124\/pharmrev.123.000938_bib17","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/eji.201848039","article-title":"Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice","volume":"49","author":"Bialojan","year":"2019","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib18","series-title":"Reference Module in Biomedical Sciences","first-page":"1","article-title":"Routes of Drug Administration","author":"Bolger","year":"2018"},{"key":"10.1124\/pharmrev.123.000938_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00291-5","article-title":"FDA approval for anifrolumab in patients with lupus","volume":"3","author":"Burki","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib20","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.addr.2011.05.017","article-title":"Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles","volume":"63","author":"Cai","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/pharmrev.123.000938_bib60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000938_bib21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ijbiomac.2021.04.054","article-title":"Docetaxel in chitosan-based nanocapsules conjugated with an anti-Tn antigen mouse\/human chimeric antibody as a promising targeting strategy of lung tumors","volume":"182","author":"Castro","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1124\/pharmrev.123.000938_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate--how does it really work?","volume":"6","author":"Chan","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.autrev.2012.03.004","article-title":"Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"11","author":"Chan","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1124\/pharmrev.123.000938_bib24","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.10615","article-title":"Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial","volume":"46","author":"Chang","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.123.000938_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.816956","article-title":"Humanized Mouse Models of Systemic Lupus Erythematosus: Opportunities and Challenges","volume":"12","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib26","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.123.000938_bib27","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/sj.jid.5700464","article-title":"New insights into the molecular control of the lymphatic vascular system and its role in disease","volume":"126","author":"Cueni","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1124\/pharmrev.123.000938_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/BOR.0000000000000381","article-title":"Treatment of lupus nephritis: current paradigms and emerging strategies","volume":"29","author":"Dall\u2019Era","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/annrheumdis-2018-214530","article-title":"Current challenges in the development of new treatments for lupus","volume":"78","author":"Dall\u2019Era","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/pharmrev.123.000938_bib30","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1177\/0961203312461291","article-title":"Pseudo-pseudo Meigs\u2019 syndrome in a patient with systemic lupus erythematosus","volume":"21","author":"Dalvi","year":"2012","journal-title":"Lupus"},{"key":"10.1124\/pharmrev.123.000938_bib31","article-title":"Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab","volume":"2017","author":"Daniel","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1124\/pharmrev.123.000938_bib32","doi-asserted-by":"crossref","first-page":"19902","DOI":"10.1073\/pnas.1313152110","article-title":"Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose","volume":"110","author":"de Titta","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.123.000938_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1051\/medsci\/2007234379","article-title":"[New routes of administration: epidermal, transcutaneous mucosal ways of vaccination]","volume":"23","author":"Denis","year":"2007","journal-title":"Med Sci (Paris)"},{"key":"10.1124\/pharmrev.123.000938_bib34","article-title":"Therapeutic effects of cationic liposomes on lupus-prone MRL\/lpr mice are mediated via inhibition of TLR4-triggered B-cell activation","volume":"40","author":"Diao","year":"2022","journal-title":"Nanomedicine (Lond)"},{"key":"10.1124\/pharmrev.123.000938_bib35","doi-asserted-by":"crossref","first-page":"8627","DOI":"10.2147\/IJN.S220754","article-title":"Co-delivery of dihydroartemisinin and HMGB1 siRNA by TAT-modified cationic liposomes through the TLR4 signaling pathway for treatment of lupus nephritis","volume":"14","author":"Diao","year":"2019","journal-title":"Int J Nanomedicine"},{"issue":"5, Suppl","key":"10.1124\/pharmrev.123.000938_bib36","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/art.1780210909","article-title":"Etiology and pathogenesis of a spontaneous lupus-like syndrome in mice","volume":"21","author":"Dixon","year":"1978","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.123.000938_bib37","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner","year":"2019","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.123.000938_bib38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jconrel.2021.07.005","article-title":"Polymeric microneedle-mediated transdermal delivery of melittin for rheumatoid arthritis treatment","volume":"336","author":"Du","year":"2021","journal-title":"J Control Release"},{"key":"10.1124\/pharmrev.123.000938_bib39","series-title":"Biomaterials for Cancer Therapeutics","first-page":"527","article-title":"19 - Lymph node targeting for improved potency of cancer vaccine","author":"Du","year":"2020"},{"key":"10.1124\/pharmrev.123.000938_bib40","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.123.000938_bib41","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1038\/s41598-020-62124-6","article-title":"Low-dose 17\u03b1-ethinyl estradiol (EE) exposure exacerbates lupus renal disease and modulates immune responses to TLR7\/9 agonists in genetically autoimmune-prone mice","volume":"10","author":"Edwards","year":"2020","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.123.000938_bib42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2012.05.017","article-title":"T cells, murine chronic graft-versus-host disease and autoimmunity","volume":"39","author":"Eisenberg","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1124\/pharmrev.123.000938_bib43","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cmet.2017.07.020","article-title":"The Lymphatic Vasculature: Its Role in Adipose Metabolism and Obesity","volume":"26","author":"Escobedo","year":"2017","journal-title":"Cell Metab"},{"key":"10.1124\/pharmrev.123.000938_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000310","article-title":"Changing paradigms in the treatment of systemic lupus erythematosus","volume":"6","author":"Fanouriakis","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1124\/pharmrev.123.000938_bib45","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/pharmrev.123.000938_bib46","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.161351","article-title":"Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: Diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1124\/pharmrev.123.000938_bib48","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/art.21039","article-title":"Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual","volume":"52","author":"Fessler","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.123.000938_bib49","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1470-2045(01)00519-8","article-title":"Lymph-node metastases in patients with melanoma: what is the optimum management?","volume":"2","author":"Fife","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1124\/pharmrev.123.000938_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106220","article-title":"Long-acting drugs and formulations for the treatment and prevention of HIV infection","volume":"57","author":"Flexner","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/pharmrev.123.000938_bib51","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.123.000938_bib52","doi-asserted-by":"crossref","first-page":"7203","DOI":"10.1021\/jacs.6b13231","article-title":"Next Generation Precision-Polyesters Enabling Optimization of Ligand-Receptor Stoichiometry for Modular Drug Delivery","volume":"139","author":"Ganugula","year":"2017","journal-title":"J Am Chem Soc"},{"key":"10.1124\/pharmrev.123.000938_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb3900","article-title":"A highly potent lymphatic system-targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus","volume":"6","author":"Ganugula","year":"2020","journal-title":"Sci Adv"},{"key":"10.1124\/pharmrev.123.000938_bib54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3899\/jrheum.121094","article-title":"Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study","volume":"40","author":"Gladman","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib55","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#","article-title":"Guidelines for referral and management of systemic lupus erythematosus in adults","volume":"42","author":"Gladman","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.123.000938_bib56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/jpet.119.257113","article-title":"Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems","volume":"370","author":"Glassman","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.123.000938_bib57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1258\/175404507780796433","article-title":"Systemic lupus erythematosus and hormone replacement therapy","volume":"13","author":"Gompel","year":"2007","journal-title":"Menopause Int"},{"key":"10.1124\/pharmrev.123.000938_bib58","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/0961203309104392","article-title":"Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort","volume":"18","author":"Gonz\u00e1lez","year":"2009","journal-title":"Lupus"},{"key":"10.1124\/pharmrev.123.000938_bib59","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/01.bor.0000240354.37927.dd","article-title":"Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells","volume":"18","author":"Grimaldi","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib61","first-page":"262","article-title":"The influence of endogenous and exogenous sex hormones on systemic lupus erythematosus in pre- and postmenopausal women","volume":"13","author":"Grygiel-G\u00f3rniak","year":"2014","journal-title":"Przegl Menopauz"},{"key":"10.1124\/pharmrev.123.000938_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16999-7","article-title":"A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice","volume":"7","author":"Gunawan","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.123.000938_bib63","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/annrheumdis-2011-201089","article-title":"Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study","volume":"71","author":"Hanly","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/pharmrev.123.000938_bib64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11095-010-0123-9","article-title":"Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs","volume":"28","author":"Harvey","year":"2011","journal-title":"Pharm Res"},{"key":"10.1124\/pharmrev.123.000938_bib65","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/epi-2016-0096","article-title":"DNA methylation in systemic lupus erythematosus","volume":"9","author":"Hedrich","year":"2017","journal-title":"Epigenomics"},{"key":"10.1124\/pharmrev.123.000938_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000446","article-title":"Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre","volume":"8","author":"Hill","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"4, Suppl","key":"10.1124\/pharmrev.123.000938_bib67","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.123.000938_bib68","doi-asserted-by":"crossref","first-page":"10799","DOI":"10.1039\/D0NR01308K","article-title":"A novel long-acting azathioprine polyhydroxyalkanoate nanoparticle enhances treatment efficacy for systemic lupus erythematosus with reduced side effects","volume":"12","author":"Hu","year":"2020","journal-title":"Nanoscale"},{"key":"10.1124\/pharmrev.123.000938_bib69","doi-asserted-by":"crossref","first-page":"13700","DOI":"10.1002\/anie.201604207","article-title":"Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability","volume":"55","author":"Hu","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1124\/pharmrev.123.000938_bib70","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/molecules26051247","article-title":"Key Factor Study for Generic Long-Acting PLGA Microspheres Based on a Reverse Engineering of Vivitrol\u00ae","volume":"26","author":"Hua","year":"2021","journal-title":"Molecules"},{"key":"10.1124\/pharmrev.123.000938_bib71","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1016\/j.biomaterials.2012.06.074","article-title":"The effect of targeted delivery of anti-TNF-\u03b1 oligonucleotide into CD169+ macrophages on disease progression in lupus-prone MRL\/lpr mice","volume":"33","author":"Huang","year":"2012","journal-title":"Biomaterials"},{"key":"10.1124\/pharmrev.123.000938_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000260","article-title":"TNF-\u03b1 and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus","volume":"5","author":"Idborg","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1124\/pharmrev.123.000938_bib73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/imm.13103","article-title":"Infectious processes and systemic lupus erythematosus","volume":"158","author":"Illescas-Montes","year":"2019","journal-title":"Immunology"},{"key":"10.1124\/pharmrev.123.000938_bib74","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/eji.1830180612","article-title":"The Y chromosome from autoimmune BXSB\/MpJ mice induces a lupus-like syndrome in (NZW x C57BL\/6)F1 male mice, but not in C57BL\/6 male mice","volume":"18","author":"Izui","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib75","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40824-021-00226-6","article-title":"Recent advances in transdermal drug delivery systems: a review","volume":"25","author":"Jeong","year":"2021","journal-title":"Biomater Res"},{"key":"10.1124\/pharmrev.123.000938_bib76","doi-asserted-by":"crossref","first-page":"7663","DOI":"10.1021\/acsnano.8b01249","article-title":"Micelle-Forming Dexamethasone Prodrug Attenuates Nephritis in Lupus-Prone Mice without Apparent Glucocorticoid Side Effects","volume":"12","author":"Jia","year":"2018","journal-title":"ACS Nano"},{"key":"10.1124\/pharmrev.123.000938_bib77","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1124\/pharmrev.123.000938_bib78","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/0975-3583.85260","article-title":"An overview of lymphatic vessels and their emerging role in cardiovascular disease","volume":"2","author":"Jones","year":"2011","journal-title":"J Cardiovasc Dis Res"},{"key":"10.1124\/pharmrev.123.000938_bib79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-018-0084-5","article-title":"The immunological anatomy of the skin","volume":"19","author":"Kabashima","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib80","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/sj.jid.5700126","article-title":"An important role of lymphatic vessels in the control of UVB-induced edema formation and inflammation","volume":"126","author":"Kajiya","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1124\/pharmrev.123.000938_bib81","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jconrel.2013.03.006","article-title":"PEGylation of interferon \u03b12 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases","volume":"168","author":"Kaminskas","year":"2013","journal-title":"J Control Release"},{"key":"10.1124\/pharmrev.123.000938_bib82","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/317452","article-title":"Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus","volume":"2010","author":"Kassi","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1124\/pharmrev.123.000938_bib83","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fimmu.2019.00470","article-title":"Regulation of Immune Function by the Lymphatic System in Lymphedema","volume":"10","author":"Kataru","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib84","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-10-3277","article-title":"Significance and mechanism of lymph node metastasis in cancer progression","volume":"71","author":"Kawada","year":"2011","journal-title":"Cancer Res"},{"key":"10.1124\/pharmrev.123.000938_bib85","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2174\/138161211795703780","article-title":"Humanized SCID mice models of SLE","volume":"17","author":"Kerekov","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1124\/pharmrev.123.000938_bib86","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jamcollsurg.2011.11.006","article-title":"Nanoparticle migration and delivery of Paclitaxel to regional lymph nodes in a large animal model","volume":"214","author":"Khullar","year":"2012","journal-title":"J Am Coll Surg"},{"key":"10.1124\/pharmrev.123.000938_bib87","article-title":"Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus","volume":"9","author":"Kim","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1124\/pharmrev.123.000938_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202200909","article-title":"Ovalbumin and Poly(i:c) Encapsulated Dendritic Cell-Targeted Nanoparticles for Immune Activation in the Small Intestinal Lymphatic System","volume":"11","author":"Kim","year":"2022","journal-title":"Adv Healthc Mater"},{"key":"10.1124\/pharmrev.123.000938_bib89","doi-asserted-by":"crossref","first-page":"257","DOI":"10.15171\/apb.2018.030","article-title":"Enhanced Lymphatic Uptake of Leflunomide Loaded Nanolipid Carrier via Chylomicron Formation for the Treatment of Rheumatoid Arthritis","volume":"8","author":"Krishnan","year":"2018","journal-title":"Adv Pharm Bull"},{"key":"10.1124\/pharmrev.123.000938_bib90","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1107\/S0907444910051905","article-title":"Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin)","volume":"67","author":"Kuglstatter","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/pharmrev.123.000938_bib91","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/rheumatology\/38.12.1239","article-title":"Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy","volume":"38","author":"Kung","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1124\/pharmrev.123.000938_bib92","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1191\/0961203302lu204oa","article-title":"Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE","volume":"11","author":"Lander","year":"2002","journal-title":"Lupus"},{"key":"10.1124\/pharmrev.123.000938_bib93","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2217\/nnm-2020-0192","article-title":"Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge","volume":"15","author":"Landh","year":"2020","journal-title":"Nanomedicine (Lond)"},{"key":"10.1124\/pharmrev.123.000938_bib94","first-page":"1330","article-title":"Concurrent occurrence of chylothorax, chylous ascites, and protein-losing enteropathy in systemic lupus erythematosus","volume":"29","author":"Lee","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib95","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.21037\/atm-20-6605","article-title":"Delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema","volume":"8","author":"Li","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1124\/pharmrev.123.000938_bib96","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/BOR.0000000000000412","article-title":"An update on lupus animal models","volume":"29","author":"Li","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib97","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2003.11.003","article-title":"Decreased phagocytosis of apoptotic cells in diseased SLE mice","volume":"22","author":"Licht","year":"2004","journal-title":"J Autoimmun"},{"key":"10.1124\/pharmrev.123.000938_bib98","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2337\/db21-1069","article-title":"Antibody-Mediated Targeting of a Hybrid Insulin Peptide Toward Neonatal Thymic Langerin-Positive Cells Enhances T-Cell Central Tolerance and Delays Autoimmune Diabetes","volume":"71","author":"Lin","year":"2022","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.123.000938_bib99","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s10067-019-04596-0","article-title":"Corticosteroids combined with doublet or single-agent immunosuppressive therapy for active proliferative lupus nephritis","volume":"38","author":"Liu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1124\/pharmrev.123.000938_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000259","article-title":"Accelerated model of lupus autoimmunity and vasculopathy driven by toll-like receptor 7\/9 imbalance","volume":"5","author":"Liu","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1124\/pharmrev.123.000938_bib102","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.biomaterials.2013.10.046","article-title":"The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus","volume":"35","author":"Look","year":"2014","journal-title":"Biomaterials"},{"key":"10.1124\/pharmrev.123.000938_bib103","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1172\/JCI65907","article-title":"Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice","volume":"123","author":"Look","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.123.000938_bib104","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/156652409787847263","article-title":"Cytokines in systemic lupus erythematosus","volume":"9","author":"Louren\u00e7o","year":"2009","journal-title":"Curr Mol Med"},{"key":"10.1124\/pharmrev.123.000938_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2019.06.009","article-title":"The contribution of macrophages to systemic lupus erythematosus","volume":"207","author":"Ma","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib106","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/RHU.0b013e3182847260","article-title":"Chylous ascites and chylothorax as presentation of a systemic progression of discoid lupus","volume":"19","author":"Manzella","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib107","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jconrel.2018.11.002","article-title":"Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension","volume":"292","author":"Mc Crudden","year":"2018","journal-title":"J Control Release"},{"key":"10.1124\/pharmrev.123.000938_bib108","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/rheumatology\/kex395","article-title":"Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register","volume":"57","author":"McCarthy","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1124\/pharmrev.123.000938_bib109","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41584-020-0462-9","article-title":"Targeted delivery of immunosuppressant in SLE","volume":"16","author":"McHugh","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2005.05.006","article-title":"Subcutaneous drug delivery and the role of the lymphatics","volume":"2","author":"McLennan","year":"2005","journal-title":"Drug Discov Today Technol"},{"key":"10.1124\/pharmrev.123.000938_bib111","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00195291","article-title":"The lupus-prone BXSB strain: the Yaa gene model of systemic lupus erythematosus","volume":"14","author":"Merino","year":"1992","journal-title":"Springer Semin Immunopathol"},{"key":"10.1124\/pharmrev.123.000938_bib112","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.123.000938_bib113","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11095-012-0884-4","article-title":"Rapid lymph accumulation of polystyrene nanoparticles following pulmonary administration","volume":"30","author":"Mohammad","year":"2013","journal-title":"Pharm Res"},{"key":"10.1124\/pharmrev.123.000938_bib114","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gfw068","article-title":"Con: Cyclophosphamide for the treatment of lupus nephritis","volume":"31","author":"Mok","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/pharmrev.123.000938_bib115","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41590-021-00914-4","article-title":"Promise and complexity of lupus mouse models","volume":"22","author":"Moore","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib116","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2215\/CJN.02271205","article-title":"A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years","volume":"1","author":"Moroni","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.123.000938_bib117","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/art.1780221105","article-title":"A Y chromosome associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation","volume":"22","author":"Murphy","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.123.000938_bib118","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0162-3109(92)90064-J","article-title":"In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL\/lpr-lpr mouse","volume":"24","author":"Nicoletti","year":"1992","journal-title":"Immunopharmacology"},{"key":"10.1124\/pharmrev.123.000938_bib119","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00296-022-05141-0","article-title":"Nanotechnology applications in rheumatology","volume":"42","author":"Nune","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1124\/pharmrev.123.000938_bib120","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1191\/096120300678828794","article-title":"Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus","volume":"9","author":"Ostensen","year":"2000","journal-title":"Lupus"},{"key":"10.1124\/pharmrev.123.000938_bib121","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.4049\/jimmunol.1501603","article-title":"Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice","volume":"195","author":"Otomo","year":"2015","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev-bioeng-112315-031200","article-title":"The Lymphatic System in Disease Processes and Cancer Progression","volume":"18","author":"Padera","year":"2016","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1124\/pharmrev.123.000938_bib123","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/13543776.2020.1720649","article-title":"Solid lipid nanoparticles: a review on recent perspectives and patents","volume":"30","author":"Paliwal","year":"2020","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/pharmrev.123.000938_bib124","doi-asserted-by":"crossref","first-page":"9838","DOI":"10.1073\/pnas.88.21.9838","article-title":"Lymphoid organs function as major reservoirs for human immunodeficiency virus","volume":"88","author":"Pantaleo","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.123.000938_bib125","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3349\/ymj.1999.40.4.343","article-title":"Elevated serum interleukin-15 levels in systemic lupus erythematosus","volume":"40","author":"Park","year":"1999","journal-title":"Yonsei Med J"},{"key":"10.1124\/pharmrev.123.000938_bib126","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.xphs.2018.07.032","article-title":"Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman primates","volume":"107","author":"Perazzolo","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1124\/pharmrev.123.000938_bib127","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1690","article-title":"Recent advances in combination of microneedles and nanomedicines for lymphatic targeted drug delivery","volume":"13","author":"Permana","year":"2021","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1124\/pharmrev.123.000938_bib128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2019.10.004","article-title":"Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis","volume":"316","author":"Permana","year":"2019","journal-title":"J Control Release"},{"key":"10.1124\/pharmrev.123.000938_bib129","article-title":"Murine models of systemic lupus erythematosus","volume":"2011","author":"Perry","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1124\/pharmrev.123.000938_bib130","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.123.000938_bib131","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.10364","article-title":"Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"46","author":"Petri","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.123.000938_bib132","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2197","article-title":"Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs","volume":"6","author":"Porter","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.123.000938_bib133","series-title":"StatPearls","article-title":"Drug Bioavailability","author":"Price","year":"2023"},{"key":"10.1124\/pharmrev.123.000938_bib134","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jconrel.2013.04.027","article-title":"Expansion of the lymphatic vasculature in cancer and inflammation: new opportunities for in vivo imaging and drug delivery","volume":"172","author":"Proulx","year":"2013","journal-title":"J Control Release"},{"key":"10.1124\/pharmrev.123.000938_bib135","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jconrel.2020.10.036","article-title":"Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach","volume":"329","author":"Qin","year":"2021","journal-title":"J Control Release"},{"key":"10.1124\/pharmrev.123.000938_bib136","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jconrel.2022.11.005","article-title":"Inflammation-responsive nanoparticles suppress lymphatic clearance for prolonged arthritis therapy","volume":"352","author":"Qin","year":"2022","journal-title":"J Control Release"},{"key":"10.1124\/pharmrev.123.000938_bib137","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/jps.21970","article-title":"Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery","volume":"99","author":"Rao","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1124\/pharmrev.123.000938_bib138","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4049\/jimmunol.129.1.236","article-title":"A high frequency idiotypic marker of anti-DNA autoantibodies in MRL-Ipr\/Ipr mice","volume":"129","author":"Rauch","year":"1982","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib139","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/wnan.48","article-title":"Nanoparticles in sentinel lymph node mapping","volume":"1","author":"Ravizzini","year":"2009","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1124\/pharmrev.123.000938_bib140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.it.2009.06.003","article-title":"Induction of autoimmunity by pristane and other naturally occurring hydrocarbons","volume":"30","author":"Reeves","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib141","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1385\/IR:25:2:143","article-title":"Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL\/lpr mice","volume":"25","author":"Reilly","year":"2002","journal-title":"Immunol Res"},{"key":"10.1124\/pharmrev.123.000938_bib142","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00281-014-0428-6","article-title":"The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved","volume":"36","author":"Rekvig","year":"2014","journal-title":"Semin Immunopathol"},{"key":"10.1124\/pharmrev.123.000938_bib143","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000199","article-title":"Mouse models of lupus: what they tell us and what they don\u2019t","volume":"5","author":"Richard","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1124\/pharmrev.123.000938_bib144","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.biopha.2016.08.020","article-title":"Application of nanoparticle technology in the treatment of Systemic lupus erythematous","volume":"83","author":"Rostamzadeh","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"10.1124\/pharmrev.123.000938_bib145","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"issue":"Suppl 5","key":"10.1124\/pharmrev.123.000938_bib146","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1289\/ehp.99107s5713","article-title":"New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects","volume":"107","author":"Rudofsky","year":"1999","journal-title":"Environ Health Perspect"},{"key":"10.1124\/pharmrev.123.000938_bib147","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2013.08.004","article-title":"PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin","volume":"172","author":"Ryan","year":"2013","journal-title":"J Control Release"},{"key":"10.1124\/pharmrev.123.000938_bib148","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2014.04.051","article-title":"Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers","volume":"193","author":"Ryan","year":"2014","journal-title":"J Control Release"},{"key":"10.1124\/pharmrev.123.000938_bib149","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.addr.2019.10.004","article-title":"Intradermal and transdermal drug delivery using microneedles - Fabrication, performance evaluation and application to lymphatic delivery","volume":"153","author":"Sabri","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/pharmrev.123.000938_bib150","doi-asserted-by":"crossref","first-page":"10934","DOI":"10.1073\/pnas.92.24.10934","article-title":"Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB\/c mice treated with pristane","volume":"92","author":"Satoh","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.123.000938_bib151","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/annrheumdis-2022-eular.4162","article-title":"POS0186 VOCLOSPORIN FOR LUPUS NEPHRITIS: RESULTS OF THE TWO-YEAR AURORA 2 CONTINUATION STUDY","volume":"81","author":"Saxena","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/pharmrev.123.000938_bib152","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41578-019-0110-7","article-title":"Material design for lymph node drug delivery","volume":"4","author":"Schudel","year":"2019","journal-title":"Nat Rev Mater"},{"key":"10.1124\/pharmrev.123.000938_bib153","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3389\/fimmu.2019.00519","article-title":"Lymphatic Function in Autoimmune Diseases","volume":"10","author":"Schwartz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib154","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1124\/jpet.103.052522","article-title":"Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs","volume":"306","author":"Shackleford","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.123.000938_bib155","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/BOR.0b013e328349a255","article-title":"Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells","volume":"23","author":"Shin","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.725325","article-title":"Interferon Genes Are Influenced by 17\u03b2-Estradiol in SLE","volume":"12","author":"Singh","year":"2021","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib157","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/13697137.2022.2050205","article-title":"Hormone therapy effect on menopausal systemic lupus erythematosus patients: a systematic review","volume":"25","author":"Soares-Jr","year":"2022","journal-title":"Climacteric"},{"key":"10.1124\/pharmrev.123.000938_bib158","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202004205","article-title":"Targeted Delivery of Cell Softening Micelles to Schlemm\u2019s Canal Endothelial Cells for Treatment of Glaucoma","volume":"16","author":"Stack","year":"2020","journal-title":"Small"},{"key":"10.1124\/pharmrev.123.000938_bib159","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.vaccine.2010.11.010","article-title":"PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration","volume":"29","author":"Stano","year":"2011","journal-title":"Vaccine"},{"key":"10.1124\/pharmrev.123.000938_bib160","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1021\/acs.molpharmaceut.0c00562","article-title":"Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV","volume":"17","author":"Stevens","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1124\/pharmrev.123.000938_bib161","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaut.2019.05.005","article-title":"IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent","volume":"102","author":"Stremska","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1124\/pharmrev.123.000938_bib162","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coi.2016.09.001","article-title":"T cells in Systemic Lupus Erythematosus","volume":"43","author":"Su\u00e1rez-Fueyo","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib163","series-title":"Biomaterials Science","first-page":"360","article-title":"Microparticles and Nanoparticles","author":"Suri","year":"2013"},{"key":"10.1124\/pharmrev.123.000938_bib164","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0065-2776(08)60342-9","article-title":"Murine Models of Systemic Lupus Erythematosus","author":"Theofilopoulos","year":"1985"},{"key":"10.1124\/pharmrev.123.000938_bib165","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1089\/jir.2011.0092","article-title":"Intracellular nucleic acid sensors and autoimmunity","volume":"31","author":"Theofilopoulos","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"10.1124\/pharmrev.123.000938_bib166","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.4049\/jimmunol.1103545","article-title":"Impaired humoral immunity and tolerance in K14-VEGFR-3-Ig mice that lack dermal lymphatic drainage","volume":"189","author":"Thomas","year":"2012","journal-title":"J Immunol"},{"issue":"suppl_1","key":"10.1124\/pharmrev.123.000938_bib167","first-page":"i3","article-title":"Systemic lupus erythematosus diagnosis and management","volume":"56","author":"Thong","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1124\/pharmrev.123.000938_bib168","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.123.000938_bib169","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000239","article-title":"Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments","volume":"4","author":"Touma","year":"2017","journal-title":"Lupus Sci Med"},{"key":"10.1124\/pharmrev.123.000938_bib170","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.123.000938_bib171","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1124\/dmd.105.008102","article-title":"An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat","volume":"34","author":"Trevaskis","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.123.000938_bib172","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/art.22198","article-title":"The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Tseng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.123.000938_bib173","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib174","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jfma.2021.03.019","article-title":"Immunometabolism in systemic lupus erythematosus: Relevant pathogenetic mechanisms and potential clinical applications","volume":"120","author":"Tzeng","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"10.1124\/pharmrev.123.000938_bib175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232416030","article-title":"DNA Nanoflowers\u2019 Amelioration of Lupus Symptoms in Mice via Blockade of TLR7\/9's Signal","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1124\/pharmrev.123.000938_bib176","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.biomaterials.2017.02.037","article-title":"Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer","volume":"127","author":"Wang","year":"2017","journal-title":"Biomaterials"},{"key":"10.1124\/pharmrev.123.000938_bib177","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1006\/clim.2001.5079","article-title":"NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci","volume":"100","author":"Waters","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1124\/pharmrev.123.000938_bib178","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1080\/10717544.2022.2120566","article-title":"Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer","volume":"29","author":"Wathoni","year":"2022","journal-title":"Drug Deliv"},{"key":"10.1124\/pharmrev.123.000938_bib179","series-title":"Primer on the rheumatic diseases","author":"Weyand","year":"2001"},{"key":"10.1124\/pharmrev.123.000938_bib180","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1124\/jpet.109.154542","article-title":"Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU","volume":"331","author":"White","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.123.000938_bib181","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fmed.2020.00303","article-title":"Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents","volume":"7","author":"Wise","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1124\/pharmrev.123.000938_bib182","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0961203313503912","article-title":"Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)","volume":"22","author":"Witt","year":"2013","journal-title":"Lupus"},{"key":"10.1124\/pharmrev.123.000938_bib183","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/rheumatology\/39.10.1078","article-title":"Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus","volume":"39","author":"Wong","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1124\/pharmrev.123.000938_bib184","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/joim.13448","article-title":"The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous","volume":"291","author":"Woo","year":"2022","journal-title":"J Intern Med"},{"key":"10.1124\/pharmrev.123.000938_bib185","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-981-15-3449-2_7","article-title":"The Epigenetics of Lupus Erythematosus","volume":"1253","author":"Wu","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/pharmrev.123.000938_bib186","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.988512","article-title":"Imbalance of helper T cell type 1, helper T cell type 2 and associated cytokines in patients with systemic lupus erythematosus: A meta-analysis","volume":"13","author":"Xiang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.123.000938_bib187","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1517\/17425240903085128","article-title":"Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies","volume":"6","author":"Xie","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1124\/pharmrev.123.000938_bib188","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/17460441.2022.2050691","article-title":"Animal models of systemic lupus erythematosus and their applications in drug discovery","volume":"17","author":"Xin","year":"2022","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/pharmrev.123.000938_bib189","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrrheum.2013.157","article-title":"Pragmatic approaches to therapy for systemic lupus erythematosus","volume":"10","author":"Xiong","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102890","article-title":"Pathological mechanisms and crosstalk among different forms of cell death in systemic lupus erythematosus","volume":"132","author":"Xu","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1124\/pharmrev.123.000938_bib191","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.addr.2011.05.019","article-title":"Intestinal lymphatic transport for drug delivery","volume":"63","author":"Y\u00e1\u00f1ez","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/pharmrev.123.000938_bib192","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijbiomac.2018.11.230","article-title":"Enhanced transdermal lymphatic delivery of doxorubicin via hyaluronic acid based transfersomes\/microneedle complex for tumor metastasis therapy","volume":"125","author":"Yang","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"10.1124\/pharmrev.123.000938_bib193","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ekir.2021.12.005","article-title":"Long-Term Results of Triple Immunosuppression With Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis","volume":"7","author":"Yap","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1124\/pharmrev.123.000938_bib194","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/14397595.2018.1493909","article-title":"Emerging targets for the treatment of lupus erythematosus: There is no royal road to treating lupus","volume":"29","author":"Yasuda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1124\/pharmrev.123.000938_bib195","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1080\/10717544.2018.1482973","article-title":"Improved lymphatic targeting: effect and mechanism of synthetic borneol on lymph node uptake of 7-ethyl-10-hydroxycamptothecin nanoliposomes following subcutaneous administration","volume":"25","author":"Ye","year":"2018","journal-title":"Drug Deliv"},{"key":"10.1124\/pharmrev.123.000938_bib196","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/ecco-jcc\/jjaa200","article-title":"Chylomicrons-Simulating Sustained Drug Release in Mesenteric Lymphatics for the Treatment of Crohn\u2019s-Like Colitis","volume":"15","author":"Yin","year":"2021","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1124\/pharmrev.123.000938_bib197","doi-asserted-by":"crossref","first-page":"R118","DOI":"10.1186\/ar2326","article-title":"Increased lymphangiogenesis in joints of mice with inflammatory arthritis","volume":"9","author":"Zhang","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1124\/pharmrev.123.000938_bib198","first-page":"247","article-title":"Recent advances in lymphatic targeted drug delivery system for tumor metastasis","volume":"11","author":"Zhang","year":"2014","journal-title":"Cancer Biol Med"},{"key":"10.1124\/pharmrev.123.000938_bib199","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1166\/jbn.2019.2777","article-title":"Albumin Based Nanomedicine for Enhancing Tacrolimus Safety and Lymphatic Targeting Efficiency","volume":"15","author":"Zhang","year":"2019","journal-title":"J Biomed Nanotechnol"},{"key":"10.1124\/pharmrev.123.000938_bib200","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.apsb.2020.12.022","article-title":"An update on oral drug delivery via intestinal lymphatic transport","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/pharmrev.123.000938_bib201","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jconrel.2012.12.018","article-title":"A self-assembled nanocarrier loading teniposide improves the oral delivery and drug concentration in tumor","volume":"166","author":"Zhang","year":"2013","journal-title":"J Control Release"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972400615X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972400615X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.123.000938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T09:15:33Z","timestamp":1739870133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003169972400615X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":200,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S003169972400615X"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.123.000938","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.123.000938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}